Filings In The Second Half Could Be Transformative For The Medicines Co.
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Co.’s transition away from near-total reliance on Angiomax seems ever closer to reality, given its full pipeline and intensive business development activities. The new products stretch beyond the hospital catheterization lab, as the company builds franchises in hospital anti-infectives, pain management, and hemostatis.